NASDAQ · CVRX
Healthcare · Medical - Devices
$3.05
Up+$0.04 (+1.33%)
Updated Sep 8, 2026, 10:32 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CVRX closed at $3.05 after 20 trading sessions, up 28.69% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $2.99 | $3.11 | $2.96 | $3.05 | 856.03K |
| Sep 3, 2026 | $3.11 | $3.175 | $2.98 | $3.01 | 614.54K |
| Sep 2, 2026 | $3.06 | $3.16 | $2.962 | $3.07 | 530.03K |
| Sep 1, 2026 | $2.93 | $3.06 | $2.895 | $3.04 | 780.72K |
| Aug 31, 2026 | $2.97 | $2.99 | $2.81 | $2.96 | 737.78K |
| Aug 28, 2026 | $3.03 | $3.15 | $2.94 | $2.95 | 497.12K |
| Aug 27, 2026 | $3.25 | $3.29 | $3.02 | $3.04 | 449.03K |
| Aug 26, 2026 | $3.31 | $3.40 | $3.15 | $3.27 | 884.49K |
| Aug 25, 2026 | $3.17 | $3.42 | $3.1303 | $3.37 | 1.12M |
| Aug 24, 2026 | $2.99 | $3.29 | $2.86 | $3.15 | 1.62M |
| Aug 21, 2026 | $2.86 | $2.96 | $2.82 | $2.84 | 742.07K |
| Aug 20, 2026 | $2.81 | $2.9507 | $2.77 | $2.84 | 746.5K |
| Aug 19, 2026 | $2.75 | $2.85 | $2.73 | $2.82 | 586.68K |
| Aug 18, 2026 | $2.77 | $2.99 | $2.705 | $2.75 | 639.09K |
| Aug 17, 2026 | $3.04 | $3.08 | $2.74 | $2.75 | 1.04M |
| Aug 14, 2026 | $3.08 | $3.24 | $2.90 | $3.08 | 1.9M |
| Aug 13, 2026 | $2.65 | $2.97 | $2.65 | $2.94 | 1.22M |
| Aug 12, 2026 | $2.55 | $2.74 | $2.50 | $2.73 | 1.37M |
| Aug 11, 2026 | $2.31 | $2.68 | $2.31 | $2.60 | 2.59M |
| Aug 10, 2026 | $2.39 | $2.39 | $2.20 | $2.37 | 2.78M |
The latest Smart Investors Daily articles mentioning CVRX.
CVRX research
Company profile and research snapshot.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 7, 2026 | Lake Street | Hold | — |
| Apr 14, 2026 | Canaccord Genuity | Buy | — |
| Feb 13, 2026 | Canaccord Genuity | Buy | — |
| Nov 6, 2025 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 24, 2026
Delivers Letter to the CVRx Board Highlighting Significant Value Proposition of Barostim to a Large Medical Device Company with Established Infrastructure to Capitalize on the Product's Market PositionBLOOMFIELD
Benzinga · Aug 17, 2026
Cantor Fitzgerald analyst Sarah James maintains CVRx (NASDAQ:CVRX) with a Overweight and lowers the price target from $13 to $5.
Yahoo · Aug 13, 2026
U.S. heart failure revenue surged 21% amid reimbursement gains and sales expansion challenges.
Yahoo · Aug 13, 2026
CVRx (NASDAQ:CVRX) outlined its efforts to expand adoption of its Barostim therapy for heart failure patients, emphasizing sales-force execution, payer coverage progress and a large post-market clinical trial during Canaccord Genuity’s 46th Annual Growth Conference. President and CEO Kevin Hykes sa
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CVRX.
